Innovest Global, Inc.
is a diversified Public Holding company that is already a ten-bagger this year
with much more on the way based on fundamentals AND technicals!

IVST massive breaking

IVST is pleased
to announce that the acquisition of Authority National Supply (ANS) is closed.
ANS was our sixth transaction to date, and has generated $22.8 million in sales
through the first three quarters of 2018. IVST
now has approximately 55 employees and $34 million in annual run-rate revenue.

Innovest Global
Signed LOI to Acquire Midwest Curtainwalls, a $12 Million Revenue and
Profitable Business. Midwest is a company that will add to our Construction and
Building Materials efforts. They generate $10-$12 million in annual revenue
from specialty commercial construction contracts, with projections of $2.4
million in profit from current contract

Innovest Global, Inc.
(OTC Markets: IVST) is in the
Conglomerates industry, a diversified holding company with operations in
commercial and industrial products and services, energy, biotechnology, and
health services. Our primary growth strategy is to acquire niche, high-growth
businesses that are capable of generating significant annual revenue. Planned
subsidiaries operate across telehealth, biotech, building materials, commercial
energy, business-to-business distribution, national call center and auto sales.

Based out of Cleveland, Ohio, IVST is easily one of the better fundamental companies trading on
the OTC marketplace. Innovest Global,
is already up 10-fold in 2018, after starting off 2018 around $0.02
before shooting to an all-time high of $0.50 in March 2018. IVST continues to hold onto the nice
gains thus far holding strong in the .25-.30 range ready for the next leg back
into the .50 range it tested earlier this year. Based upon the company’s strong
fundamental AND technical picture, Innovest
Global, Inc
. could easily retake its all-time high by the end of 2018.

Whata stock
structure IVST has folks! The
company has an amazing unchanged free-trading float of 11,796,710 common shares
with no convertible debts, no warrants or options outstanding,
and employs 45.

Onto the meat and potatoes:

IVST owns 20% of StemVax Therapeutics which is the first
company in its Biotech Division.

StemVax Therapeutics
is a Translational Biotechnology Company that develops novel therapies for
brain tumor patients. We focus our efforts on developing immunotherapeutic
approaches to treating patients with Glioblastoma Multiforme (GBM), a
devastating brain cancer. We also focus our research efforts on novel drug
development to target Cancer Stem cells and other multi-resistant cancer cells.
Lead by world-renowned neuroscientist, Dr. Dwain Morris-Irvin, the Biotech
& Health Sciences Division is currently focused on commercializing StemVax’s cancer vaccination therapy
technology. The cancer vaccination therapy technology was just recently awarded
a U.S. patent! We seek to make a difference in patient’s lives bringing new
beginnings to the market by developing novel therapeutics.

IVST’s management
team has been extremely busy with its pending mega-acquisition of a building
materials company, which produces $30
in annual revenues! Once the building materials company is
acquired, it will serve as Innovest
third division. The initial discussions began back in March 2018,
followed by formal negotiations in April 2018. In June, Innovest management formally proposed the acquisition pitch to the
target company’s board of directors. Upon conclusion of the presentation, both
parties had signed and executed a Letter of Intent (LOI) document. In late
August 2018, it was announced that both parties have effectively reached an
agreement on the acquisition transaction structure and long form documents. We
expect this to “formally” close at any moment.

IVST has the
vision and model of Berkshire-Hathaway, we look forward to its evolution!